Literature DB >> 8212522

The pharmacokinetics of primaquine in calves after subcutaneous and intravenous administration.

H Yoshimura1, Y S Endoh, Y Ishihara, S Nakamura, Y Inoue.   

Abstract

The pharmacokinetics of primaquine was studied in calves of 180-300 kg live weight. Primaquine was injected at 0.29 mg/kg (0.51 mg/kg as primaquine diphosphate) intravenously (IV) or subcutaneously (SC) and the plasma concentrations of primaquine and its metabolite carboxyprimaquine were determined by high-performance liquid chromatography. The extrapolated concentration of primaquine at zero time after IV administration was 0.50 +/- 0.48 microgram/ml (mean +/- SD) which decreased with an elimination half-life of 0.16 +/- 0.07 h. Primaquine was rapidly converted to carboxyprimaquine after either route of administration. The peak concentration of carboxyprimaquine was 0.50 +/- 0.08 microgram/ml at 1.67 +/- 0.15 h after IV administration. The corresponding value was 0.47 +/- 0.07 micrograms/ml at 5.05 +/- 1.20 h after SC administration. The elimination half-lives of carboxyprimaquine after IV and SC administration were 15.06 +/- 0.99 and 12.26 +/- 3.06 h, respectively. The areas under the concentration-time curve for carboxyprimaquine were similar following either IV or SC administration of primaquine; the values were 11.85 +/- 2.62 micrograms.h/ml after the former and 10.95 +/- 2.65 micrograms.h/ml after the latter. The mean area under the concentration-time curve for primaquine was less than 0.1 micrograms.h/ml after either route of administration.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8212522     DOI: 10.1007/bf01839241

Source DB:  PubMed          Journal:  Vet Res Commun        ISSN: 0165-7380            Impact factor:   2.459


  15 in total

1.  Neurotoxicity of the 8-aminoquinolines. III. The effects of pentaquine, isopentaquine, primaquine, and pamaquine on the central nervous system of the rhesus monkey.

Authors:  I G SCHMIDT; L H SCHMIDT
Journal:  J Neuropathol Exp Neurol       Date:  1951-07       Impact factor: 3.685

2.  High-performance liquid chromatographic--electrochemical assay method for primaquine in plasma and urine.

Authors:  M V Nora; G W Parkhurst; R W Thomas; P E Carson
Journal:  J Chromatogr       Date:  1984-05-11

3.  In vitro effects of primaquine and primaquine metabolites on exoerythrocytic stages of Plasmodium berghei.

Authors:  M D Bates; S R Meshnick; C I Sigler; P Leland; M R Hollingdale
Journal:  Am J Trop Med Hyg       Date:  1990-06       Impact factor: 2.345

4.  Elimination of the gametocytes of Theileria annulata of cattle by primaquin phosphate.

Authors:  Z H Zhang
Journal:  Vet Parasitol       Date:  1987-01       Impact factor: 2.738

5.  Structure-activity relationships of putative primaquine metabolites causing methemoglobin formation in canine hemolysates.

Authors:  C M Link; A D Theoharides; J C Anders; H Chung; C J Canfield
Journal:  Toxicol Appl Pharmacol       Date:  1985-11       Impact factor: 4.219

6.  Subacute toxicity of primaquine in dogs, monkeys, and rats.

Authors:  C C Lee; L D Kinter; M H Heiffer
Journal:  Bull World Health Organ       Date:  1981       Impact factor: 9.408

7.  Excretion, distribution, and metabolism of primaquine in rats.

Authors:  A M Clark; J K Baker; J D McChesney
Journal:  J Pharm Sci       Date:  1984-04       Impact factor: 3.534

8.  Pharmacokinetics of primaquine in man: identification of the carboxylic acid derivative as a major plasma metabolite.

Authors:  G W Mihaly; S A Ward; G Edwards; M L Orme; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

9.  Antimalarial activity and inhibition of monoamine oxidases A and B by exo-erythrocytic antimalarials. Optical isomers of primaquine, N-acylated congeners, primaquine metabolites and 5-phenoxy-substituted analogues.

Authors:  A Brossi; P Millet; I Landau; M E Bembenek; C W Abell
Journal:  FEBS Lett       Date:  1987-04-20       Impact factor: 4.124

10.  Pharmacokinetics of primaquine in man. I. Studies of the absolute bioavailability and effects of dose size.

Authors:  G W Mihaly; S A Ward; G Edwards; D D Nicholl; M L Orme; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1985-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.